PreDiabetes
Conditions
Keywords
GDF-15, Physical Exercise, Prediabetes
Brief summary
The aim of this study is to evaluate whether there is a change in GDF-15 levels in individuals with prediabetes at the 2nd hour after the first exercise and after a 12-week exercise program with guide-based exercise programs.
Detailed description
GDF-15, which has anorexigenic effects, increases with exercise. In prediabetic patients, GDF-15 is higher than healthy controls. The effect of exercise on GDF-15 levels in prediabetic patients is unknown. The aim of this study is to evaluate whether there is a change in GDF-15 levels after the application of guideline-based exercise programs in individuals with prediabetes at the 2nd hour after the first exercise and after a 12-week exercise program.
Interventions
BEHAVIORALExercise
180 minutes of moderate-intensity exercise per week
Sponsors
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)
Intervention model description
Exercise intervention will be applied to intervention group All participiants will be applied to standard recommendations
Eligibility
Sex/Gender
FEMALE
Age
30 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Body mass index 30-34.9 kg / m2 * Sedentary life-style (Physical activity below 300 kcal / day will be assessed by Minnesota Leisure Physical Activity Questionnaire) * Those who have sufficient motivation to participate in the exercise program (will be evaluated by face-to-face interview by the researchers) * Having the same weight for 6 months before participating in the study (± 2.5 kg) * Those diagnosed with prediabetes by oral glucose tolerance test and / or HbA1c measurement will be included.
Exclusion criteria
* Serious medical condition (e.g. advanced malignancy or major neurological, psychiatric or endocrine disease, respiratory failure, etc.) * Having cardiovascular disease * Having diabetes * Using metformin * Taking hormone replacement therapy * less than 1 year life expectancy * HIV positivity * Substance use * Functional dependence * Cognitive weakness * Those with other diseases that will affect the study result (respiratory diseases, muscle diseases, etc.) * Those who use drugs or supplements that will affect the results of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Level of Growth Diferantiation Factor-15 | 12 weeks | Level of Growth Diferantiation Factor-15 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Level of VO2max | 12 weeks | Level of VO2max |
Countries
Turkey (Türkiye)
Contacts
Primary ContactElif Yıldırım Ayaz, M.D.
Outcome results
None listed